lenalidomide has been researched along with Lymphoma, Non-Hodgkin in 64 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (12.50) | 29.6817 |
| 2010's | 34 (53.13) | 24.3611 |
| 2020's | 22 (34.38) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, T; Jing, F; Song, W; Wang, L; Wang, Y; Xiao, S; Xue, H | 1 |
| Chen, D; Chen, Y; Gao, J; Jia, Y; Tao, H; Wang, F; Wu, P; Zhou, Z | 1 |
| Westin, J | 1 |
| Eagers, KA; Janes, A; Moore, DC; Pineda-Roman, M | 1 |
| Álvaro-Naranjo, T; Carnicero-González, F; Casanova-Espinosa, M; de la Cruz-Merino, L; de la Cruz-Vicente, F; Espejo-García, P; Fernández-Álvarez, R; Fernández-Román, I; Gálvez-Carvajal, L; García-Domínguez, DJ; Gómez-Codina, J; Guirado-Risueño, M; Gumà-Padrò, J; Hontecillas-Prieto, L; Jiménez-Cortegana, C; Labrador, J; Martín García-Sancho, A; Martínez-Banaclocha, N; Marylene, L; Navarro, M; Nogales-Fernández, E; Palazón-Carrión, N; Provencio-Pulla, M; Ríos-Herranz, E; Rodríguez-Abreu, D; Rodríguez-García, G; Rueda-Domínguez, A; Salar-Silvestre, A; Sánchez-Beato, M; Sánchez-Margalet, V | 1 |
| Caccese, E; Messori, A | 1 |
| Cherng, HJ; Westin, JR | 1 |
| Frascione, PMM; Novo, M; Paruzzo, L; Poletto, S; Vitolo, U | 1 |
| Kameoka, Y | 1 |
| Baehring, JM; Kaulen, LD | 1 |
| Armand, P; Avigan, D; Bartlett, NL; Bitran, J; Brody, JD; Farooqui, M; Ghesquieres, H; Hamadani, M; Herrera, AF; Kanate, A; Kline, J; Kuruvilla, J; Marinello, P; Morschhauser, F; Moskowitz, CH; Ribrag, V; Schuster, SJ; Zinzani, PL | 1 |
| Karimi, Y; Phillips, TJ; Takiar, R | 1 |
| Maddocks, K; Nedved, A; Nowakowski, GS | 1 |
| Bagal, B; Bonda, A; Chatarjee, A; Dasgupta, A; Dey, S; Epari, S; Goda, J; Gupta, T; Jain, H; Kakoti, S; Khanna, N; Laskar, S; Nayak, L; Sarma, R; Sengar, M | 1 |
| Armitage, JO; Bierman, PJ; Bociek, RG; Caimi, PF; Ganguly, S; Lunning, M; Lyden, L; Meza, JL; Vose, JM | 1 |
| Aurran-Schleinitz, T; Belmecheri, N; Bladé, JS; Bouabdallah, R; Coso, D; Lopez Almeida, L; Mescam, L; Montes de Oca, C; Noel, R; Schiano de Colella, JM; Slama, B; Vey, N; Zemmour, C | 1 |
| Cordoba, R; Fleury, I; Greil, R; Hess, G; Joffe, E; Kim, K; Ku, M; Kurukulasuriya, NC; Marks, R; Mondello, P; Nowakowski, GS; Peters, A; Sabatelli, L; Salles, G; Sporchia, A; Trotman, J; Waltl, EE; Winderlich, M; Yoon, DH; Zinzani, PL | 1 |
| Baile, M; Bergua, J; Caballero, D; Campo, E; Dlouhy, I; Enjuanes, A; Espeso, M; González-Barca, E; Grande, C; Jarque, I; López-Guillermo, A; Martín García-Sancho, A; Montes-Moreno, S; Redondo, A; Rodríguez, G; Salar, A; Sancho, JM | 1 |
| Li, D; Shang, Y; Zhao, H | 1 |
| Dada, R | 1 |
| Hu, S; Wang, W; Zhang, W; Zhang, Y; Zhou, D; Zou, D | 1 |
| Brunson, A; Jonas, B; Kaesberg, P; Luxardi, G; Marusina, A; Maverakis, E; Merleev, A; Poh, C; Rosenberg, A; Tuscano, JM | 1 |
| Bartlett, NL; Blum, KA; Cheson, BD; Hsi, ED; Jung, SH; Leonard, JP; Martin, P; Pitcher, B; Ruan, J; Shea, T; Smith, SE | 1 |
| Orna, E; Sancho, JM; Sorigue, M | 1 |
| Bai, H; Fan, WJ; Fan, ZQ; Wu, T | 1 |
| He, W; Min, X; Yang, X | 1 |
| Illerhaus, G; Kasenda, B; Schorb, E | 1 |
| Geng, H; Hwang, J; Mannis, G; Rubenstein, JL; Vu, K | 1 |
| Barr, PM | 1 |
| Abramson, JS; Advani, RH; Andreadis, CB; Bartlett, N; Bellam, N; Byrd, JC; Czuczman, MS; Dwyer, MA; Fayad, LE; Glenn, MJ; Gockerman, JP; Gordon, LI; Harris, NL; Hoppe, RT; Horwitz, SM; Kelsey, CR; Kim, YH; Krivacic, S; LaCasce, AS; Nademanee, A; Naganuma, M; Porcu, P; Press, O; Pro, B; Reddy, N; Sokol, L; Swinnen, L; Tsien, C; Vose, JM; Wierda, WG; Yahalom, J; Zafar, N; Zelenetz, AD | 1 |
| Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E | 1 |
| Chang, MN; Hou, W; Jung, SH; Li, Y | 1 |
| Czuczman, MS; Habermann, TM; Li, J; Lossos, IS; Pietronigro, D; Reeder, CB; Tuscano, JM; Vose, JM; Witzig, TE; Zinzani, PL | 1 |
| Abedi, M; Brunson, A; Chee, K; Dutia, M; O'Donnell, RT; Reed-Pease, C; Tuscano, JM; Welborn, J | 1 |
| Argnani, L; Cox, MC; Devizzi, L; Di Rocco, A; Fabbri, A; Fattori, PP; Rigacci, L; Rossi, G; Storti, S; Tura, S; Vitolo, U; Zaccaria, A; Zaja, F; Zinzani, PL | 1 |
| Buske, C | 1 |
| Baladandayuthapani, V; Claret, LC; Davis, RE; Fanale, MA; Fayad, LE; Feng, L; Fowler, NH; Hagemeister, FB; Kwak, LW; McLaughlin, P; Muzzafar, T; Nastoupil, L; Neelapu, SS; Oki, Y; Orlowski, RZ; Rawal, S; Romaguera, JE; Samaniego, F; Shah, J; Tsai, KY; Turturro, F; Wang, M; Westin, JR | 1 |
| Costa, LJ; Dermer, SJ; Kumar, S; Stowell, SA | 1 |
| Choquet, S; Hoang-Xuan, K; Houillier, C; Martin-Duverneuil, N; Mokhtari, K; Navarro, S; Soussain, C; Touitou, V | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| Coyle, M; Evens, AM; Kritharis, A; Sharma, J | 1 |
| Cheson, BD; Crawford, J | 1 |
| Rosen, ST; Siddiqi, T | 1 |
| Cheah, CY; Fayad, LE; Fowler, NH; Hagemeister, FB; LeBlanc, D; Nastoupil, LJ; Neelapu, SS; Samaniego, F | 1 |
| Ar, MC; Salihoglu, A; Soysal, T | 1 |
| Baldini, L; Bari, A; Buda, G; Carella, AM; Cesaretti, M; Chiapella, A; Di Raimondo, F; Ferrari, A; Guardigni, L; Marcheselli, L; Marcheselli, R; Molinari, AL; Musto, P; Pozzi, S; Ronconi, S; Sacchi, S; Santoro, A; Silvestris, F; Specchia, G; Vallisa, D | 1 |
| Galanina, N; Nabhan, C; Petrich, A | 1 |
| Argnani, L; Cox, MC; Devizzi, L; Di Rocco, A; Fabbri, A; Fattori, PP; Rigacci, L; Rossi, G; Storti, S; Vitolo, U; Zaja, F; Zinzani, PL | 1 |
| Cole, CE; Ervin-Haynes, A; Habermann, TM; Justice, G; Lam, W; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB | 1 |
| Czuczman, MS; O'Connor, OA | 1 |
| Wiernik, PH | 1 |
| Cole, C; Ervin-Haynes, A; Justice, G; Kaplan, H; Moore, T; Pietronigro, D; Reeder, C; Takeshita, K; Voralia, M; Vose, JM; Wiernik, PH; Witzig, TE; Zeldis, JB | 1 |
| Cheson, BD; Friedberg, JW; Kahl, BS | 1 |
| Hagemeister, FB | 1 |
| Rummel, M | 1 |
| Ahmadi, T; Carver, JR; Chong, EA; Nasta, S; Schuster, SJ; Stonecypher, M; Wheeler, JE | 1 |
| Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W | 1 |
| Buckstein, R; Czuczman, MS; Ervin-Haynes, A; Li, J; Pietronigro, D; Polikoff, J; Reeder, CB; Vose, JM; Witzig, TE; Zinzani, PL | 1 |
| Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Gibson, AD; Klem, J; Price, N; Reddy, GK | 1 |
| Czuczman, MS; Hernandez-Ilizaliturri, FJ; Holkova, B; Ottman, E; Reddy, N | 1 |
| Chanan-Khan, AA; Cheson, BD | 1 |
| Corral, LG; Fleming, YW; Stein, B; Zhu, D | 1 |
15 review(s) available for lenalidomide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Treatment strategies for patients with diffuse large B-cell lymphoma.
Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Rituximab; Vincristine | 2022 |
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Central Nervous System Neoplasms; Cranial Irradiation; Cyclophosphamide; Cytarabine; Humans; Immune Checkpoint Inhibitors; Lenalidomide; Lymphoma, Non-Hodgkin; Methotrexate; Nivolumab; Pemetrexed; Procarbazine; Prospective Studies; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab; Temozolomide; Thiotepa; Vincristine | 2022 |
Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Prognosis; Prospective Studies; Venous Thromboembolism | 2018 |
[Research and Applications Progress of Lenalidomide in Relapsed / Refractory Blood System Diseases -Review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Thalidomide | 2018 |
Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nivolumab; Piperidines; Pyrazoles; Pyrimidines; Recurrence | 2018 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Prognosis; Protein-Tyrosine Kinases; Purines; Quinazolinones; Randomized Controlled Trials as Topic; Recurrence; Sulfonamides; Thalidomide; Treatment Outcome | 2015 |
Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.
Topics: Angiogenesis Inhibitors; B-Lymphocytes; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Signal Transduction; Thalidomide | 2015 |
The evolving role of lenalidomide in non-Hodgkin lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Lymphoma, Non-Hodgkin; Signal Transduction; Thalidomide; Treatment Outcome | 2016 |
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines; Thalidomide | 2008 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Lymphoma, Non-Hodgkin; Protein-Tyrosine Kinases; Radioimmunotherapy; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Secondary Prevention; Signal Transduction; Sirolimus; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide | 2010 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia | 2011 |
Lenalidomide for the treatment of B-cell malignancies.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Waldenstrom Macroglobulinemia | 2008 |
17 trial(s) available for lenalidomide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Rituximab; Treatment Outcome | 2022 |
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.
Topics: Antibodies, Monoclonal, Humanized; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local | 2023 |
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Transplantation, Autologous; Treatment Outcome | 2023 |
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prospective Studies; Rituximab; Treatment Outcome | 2023 |
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neutropenia; Rituximab; Thrombocytopenia | 2023 |
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Rituximab; Survival Rate; Thalidomide | 2017 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polymorphism, Genetic; Receptors, IgG; Rituximab; Thalidomide; Treatment Outcome | 2014 |
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Rituximab; Thalidomide; Treatment Outcome | 2014 |
A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Thalidomide | 2015 |
Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Exanthema; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Prospective Studies; Rituximab; Thalidomide | 2015 |
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Italy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Survival Rate; Thalidomide | 2016 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Thalidomide | 2008 |
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constipation; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Time Factors; Treatment Outcome | 2009 |
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2011 |
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Thalidomide; Treatment Outcome | 2011 |
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
32 other study(ies) available for lenalidomide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Frail Elderly; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisone; Retrospective Studies; Rituximab | 2022 |
Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Gastroscopy; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome; Ultrasonography | 2022 |
Always be prepared for success.
Topics: Brentuximab Vedotin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | 2022 |
Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Treatment Outcome | 2023 |
Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | 2022 |
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Retrospective Studies; Treatment Outcome | 2022 |
[Standard treatment and future perspectives for follicular lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Quality of Life; Rituximab | 2022 |
Divergent paths: management of early relapsed follicular lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Rituximab | 2022 |
Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local | 2023 |
Lenalidomide following whole-brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System; Central Nervous System Neoplasms; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large
Topics: Adolescent; Adult; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab | 2023 |
Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab; Treatment Outcome | 2023 |
The AUGMENT study: Lenalidomide in indolent lymphoma … balance the imbalance!
Topics: Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male | 2020 |
Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy | 2020 |
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Follow-Up Studies; Humans; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Rituximab | 2021 |
Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphadenopathy; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Parotid Gland; Positron Emission Tomography Computed Tomography; Rituximab; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2018 |
Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Treatment Outcome | 2019 |
Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab.
Topics: Humans; Lenalidomide; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2019 |
Non-Hodgkin's lymphomas, version 1.2013.
Topics: Antineoplastic Agents; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Thalidomide; Virus Activation | 2013 |
Designs for randomized phase II clinical trials with two treatment arms.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bias; Clinical Trials, Phase II as Topic; Endpoint Determination; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Recurrence; Research Design; Rituximab; Thalidomide; Treatment Outcome | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult | 2013 |
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Immunologic Factors; Italy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Off-Label Use; Retrospective Studies; Survival Rate; Thalidomide | 2015 |
Towards a chemotherapy-free approach in indolent lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Rituximab; Thalidomide | 2014 |
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.
Topics: Benzylamines; Cyclams; Cyclophosphamide; Data Collection; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphoma, Non-Hodgkin; Multiple Myeloma; Practice Patterns, Physicians'; Thalidomide | 2015 |
Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.
Topics: Aged; Angiogenesis Inhibitors; Central Nervous System Neoplasms; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Thalidomide | 2015 |
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2015 |
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Italy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
Topics: Adenine Nucleotides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Clofarabine; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Phosphoinositide-3 Kinase Inhibitors; Rituximab; Thalidomide | 2010 |
Myocarditis during lenalidomide therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Autopsy; Dexamethasone; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Multiple Organ Failure; Myocarditis; T-Lymphocytes; Thalidomide | 2010 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Mice; Mice, SCID; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Neoplasms; Prostatic Neoplasms; Thalidomide | 2008 |